Ventas, Incの売上高は？

Ventas, Incの2025年度の売上高は$5.8Bです（前年比+18.5%）。

Ventas, Incの純利益は？

Ventas, Incの2025年度の純利益は$262Mです（前年比+196.0%）。

Ventas, IncのROEは？

Ventas, Incの2025年度のROE（自己資本利益率）は2.1%です。

企業一覧に戻る

Ventas, Inc（VTR）の決算・業績分析

Ventas, Incの2025年有価証券報告書をAI分析。売上高$5.8B(+18.5%)。Real Estate。

SUMMARY — 業績サマリー

Ventas, Incの2025年度業績サマリー

Ventas, Inc（証券コード: VTR）の2025年度決算・業績分析。売上高は$5.8B（前年比+18.5%）。純利益は$262M（前年比+196.0%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。

Ventas, Incの2024年度注目ポイント

※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。

Revenue grew 7.9% YoY to $4.1B (XBRL), but net income fell 172.4% YoY to -$41M (XBRL).
Net debt reached $13.0B (11.8x EBITDA) (XBRL), with long-term debt at $13.5B (XBRL).
Dividends paid totaled $720M (XBRL), despite negative net income and a payout ratio of -1759.8% (XBRL).

Ventas, Incの売上高変化の要因

•Total revenue increased 7.9% YoY to $4.1B (XBRL), driven by growth strategies in senior housing and external expansion (10-K). Segment-specific revenue data is unavailable in XBRL, though NOI by segment was reported as $866M (SHOP), $579M (OM&R), and $606M (NNN) (10-K). Historical revenue growth averaged 3.7% CAGR over five years (XBRL).

Ventas, Incの営業利益変化の要因

•Operating income declined to -$94M (-2.3% margin) (XBRL), with net income falling 172.4% YoY to -$41M (XBRL). EBITDA remained strong at $1.1B (26.7% margin) (XBRL), but operating and net margins turned negative. Gross profit data is unavailable (XBRL).

Ventas, Incの事業リスクと対応

Macroeconomic trends (labor costs, inflation, interest rates) could increase expenses and reduce profitability (10-K).

NIH reimbursement caps (15% indirect cost limit) threaten tenant funding (10-K).

Rising interest rates may increase borrowing costs and reduce real estate values (10-K).

Inflation may raise operating costs, which may not be fully offset by rate increases (10-K).

U.S. political/regulatory changes may disrupt government funding for tenants (10-K).

Competition for skilled workers may force higher labor costs (10-K).

Ventas, Incの今後の見通し・業績予想

Management provided FY2025 revenue guidance of $4.5B (10-K), emphasizing growth in senior housing and serving the aging population (10-K).

Ventas, Incの事業内容

Ventas, Inc. (VTR) is a REIT specializing in healthcare real estate, generating revenue through net operating income (NOI) from senior housing, outpatient medical facilities, and triple-net leased properties (10-K). Key segments include Senior Housing Operating Portfolio (SHOP), Outpatient Medical & Research Portfolio (OM&R), and Triple-Net Leased Properties (NNN) (10-K). Competitive advantages include expertise in healthcare real estate and partnerships with industry leaders (10-K). No significant customer concentration or explicit competitors are disclosed (10-K).

Ventas, IncのAI業績分析レポート（2024年度）

Ventas, Inc. (VTR) FY2024 Annual Report Analysis

Highlights

•Revenue grew 7.9% YoY to $4.1B (XBRL), but net income fell 172.4% YoY to -$41M (XBRL).

•Net debt reached $13.0B (11.8x EBITDA) (XBRL), with long-term debt at $13.5B (XBRL).

•Dividends paid totaled $720M (XBRL), despite negative net income and a payout ratio of -1759.8% (XBRL).

Business Overview

Ventas, Inc. is a REIT focused on healthcare real estate, generating revenue through NOI from senior housing, outpatient medical facilities, and triple-net leased properties (10-K). Key segments include Senior Housing Operating Portfolio (SHOP), Outpatient Medical & Research Portfolio (OM&R), and Triple-Net Leased Properties (NNN) (10-K). Competitive advantages include expertise in healthcare real estate and partnerships with industry leaders (10-K). No significant customer concentration or explicit competitors are disclosed (10-K).

Revenue Analysis

Total revenue increased 7.9% YoY to $4.1B (XBRL), driven by growth strategies in senior housing and external expansion (10-K). Segment-specific revenue data is unavailable in XBRL, though NOI by segment was reported as $866M (SHOP), $579M (OM&R), and $606M (NNN) (10-K). Historical revenue growth averaged 3.7% CAGR over five years (XBRL).

Profitability Analysis

Operating income declined to -$94M (-2.3% margin) (XBRL), with net income falling 172.4% YoY to -$41M (XBRL). EBITDA remained strong at $1.1B (26.7% margin) (XBRL), but operating and net margins turned negative. Gross profit data is unavailable (XBRL).

Balance Sheet Analysis

Equity ratio was 38.4% (XBRL), with total assets at $24.7B (XBRL). Long-term debt rose to $13.5B (XBRL), and net debt reached $13.0B (11.8x EBITDA) (XBRL). Cash reserves stood at $509M (XBRL), but leverage remains high.

Cash Flow Analysis

Operating cash flow was $1.1B (XBRL), significantly higher than net income (-$41M). Free cash flow totaled $261M (XBRL), while investing cash flow was -$859M (XBRL). Dividends paid reached $720M (XBRL), with depreciation & amortization at $1.2B (XBRL).

Working Capital Analysis

N/A

Risks

1.Macroeconomic trends (labor costs, inflation, interest rates) could increase expenses and reduce profitability (10-K).

2.NIH reimbursement caps (15% indirect cost limit) threaten tenant funding (10-K).

3.Rising interest rates may increase borrowing costs and reduce real estate values (10-K).

4.Inflation may raise operating costs, which may not be fully offset by rate increases (10-K).

5.U.S. political/regulatory changes may disrupt government funding for tenants (10-K).

6.Competition for skilled workers may force higher labor costs (10-K).

Outlook